Holen Sie sich die Stockscreener-App
206.64
0.36%
0.75
Schlusskurs vom Vortag:
$205.89
Offen:
$205.89
24-Stunden-Volumen:
1.57M
Relative Volume:
0.82
Marktkapitalisierung:
$44.29B
Einnahmen:
$742.00K
Nettoeinkommen (Verlust:
$-1.37B
KGV:
-29.21
EPS:
-7.0731
Netto-Cashflow:
$-1.07B
1W Leistung:
+0.81%
1M Leistung:
-1.24%
6M Leistung:
+108.47%
1J Leistung:
+352.17%
1-Tages-Spanne:
$204.07
$208.82
1-Wochen-Bereich:
$200.00
$210.88
52-Wochen-Spanne:
$45.72
$224.31
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
650-481-6801
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Compare RVMD vs VRTX, MRNA, REGN, ARGX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-02-27 | Fortgesetzt | UBS | Buy |
| 2025-11-18 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-09-12 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-09-05 | Eingeleitet | Truist | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-08-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
Revolution Medicines SVP Cislini sells $158,599 in shares By Investing.com - Investing.com Australia
Form 4 Revolution Medicines Inc For: 29 September By Investing.com - Investing.com South Africa
Revolution Medicines SVP Jeff Cislini Sells 765 Shares Under 10b5-1 Trading Plan - Kalkine Media
6,000 shares from exercised options are listed for an officer’s proposed sale at Revolution Medicines (RVMD). - Stock Titan
Form 4 Revolution Medicines Inc For: 28 September By Investing.com - Investing.com South Africa
Revolution Medicines officer Mancini sells $743k in stock By Investing.com - Investing.com South Africa
Revolution Medicines officer Mancini sells $743k in stock - Investing.com
RVMD Initiates Coverage On Brookline Capital -- Rating Set to Bu - GuruFocus
Revolution Medicines Initiated at Buy by Brookline Capital - Moomoo
Brookline initiates Revolution Medicines stock with buy rating By Investing.com - Investing.com Nigeria
Brookline Capital Initiates Revolution Medicines(RVMD.US) With Buy Rating, Announces Target Price $318 - Moomoo
Form 144 REVOLUTION MEDICINES INC For: 27 September By Investing.com - Investing.com South Africa
How a UCSF scientist's persistence led to a $1 million prize and groundbreaking cancer drug - The Business Journals
Stock options are the source of 9,363 shares a Revolution Medicines (RVMD) officer proposes to sell. - Stock Titan
Form 144 Revolution Medicines For: 25 September By Investing.com - Investing.com Nigeria
Form 144 Revolution Medicines For: 25 September - Investing.com India
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? - Yahoo Finance
Revolution Medicines director Elizabeth Anderson sells $1.96m in stock By Investing.com - Investing.com Nigeria
Revolution Medicines director Elizabeth Anderson sells $1.96m in stock - Investing.com
Form 4 Revolution Medicines Inc For: 24 September - Investing.com India
Form 4 Revolution Medicines Inc For: 24 September By Investing.com - Investing.com Canada
Revolution Medicines Gains as New Buy Rating Adds to Recent Regulatory Momentum - Quiver Quantitative
After three earlier sales, an officer proposes selling 587 more Revolution Medicines (RVMD) shares. - Stock Titan
Revolution Medicine’s $39,800-Monthly Cancer Drug Puts Access In Focus — CEO Goldsmith Expects Insurers To Move ‘Swiftly’ To Provide Coverage - Stocktwits
Revolution Medicines Price Target Announced at $267.00/Share by Goldman Sachs - moomoo.com
Goldman Sachs Reinitiates Buy on RVMD with $267 Target Amid Biot - gurufocus.com
How (RVMD) Movements Inform Risk Allocation Models - Stock Traders Daily
Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing? - Yahoo Finance
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib - markets.businessinsider.com
Form 4 Revolution Medicines Inc For: 22 September By Investing.com - Investing.com Australia
Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE - Yahoo Finance
Revolution Medicines (NASDAQ: RVMD) director plans stock sale from option exercise - Stock Titan
Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today - Benzinga
AIM ImmunoTech Highlights Ampligen’s Potential Role in the - GlobeNewswire
Illinois grew the science behind a breakthrough cancer drug — but couldn’t hold onto the company - Crain's Chicago Business
RVMD Maintained by B of A Securities -- Price Target Raised to $265 - GuruFocus
Client Revolution Medicines Secures 672,000-Square-Foot Redwood City Lease in former Google Space - Procopio
Revolution Medicines, Inc. (RVMD) Stock Analysis: A Promising 31.56% Upside in the Precision Oncology Space - DirectorsTalk Interviews
Revolution Medicines, Inc.(NasdaqGS: RVMD) added to FTSE All-World Index - marketscreener.com
This Insider Has Just Sold Shares In Revolution Medicines - simplywall.st
Revolution Medicines chief development officer sells $67,940 in stock By Investing.com - Investing.com South Africa
Revolution Medicines Senior Advisor Executes Stock Sales via 10b5-1 Plan to Cover RSU Taxes - Kalkine Media
Revolution Medicines officer sells $353,449 in shares By Investing.com - Investing.com Nigeria
Revolution Medicines chief development officer sells $67,940 in stock - Investing.com
Revolution Medicines’ senior advisor sells $1.1m in stock By Investing.com - Investing.com South Africa
Revolution Medicines CFO Jack Anders sells $807,513 in stock By Investing.com - Investing.com Australia
Revolution Medicines’ senior advisor sells $1.1m in stock - Investing.com
Revolution Medicines’ Jeff Cislini sells $670k in common stock By Investing.com - Investing.com Australia
Revolution Medicines COO Margaret Horn sells $989,612 of common stock By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark Goldsmith sells $2.78m in stock - Investing.com
Revolution Medicines’ Jeff Cislini sells $670k in common stock - Investing.com
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Revolution Medicines Inc-Aktie (RVMD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sandler Alan B. | Chief Development Officer |
Sep 29 '26 |
Sale |
202.14 |
6,309 |
1,275,294 |
52,559 |
| Cislini Jeff | SVP & General Counsel |
Sep 25 '26 |
Sale |
207.32 |
765 |
158,600 |
51,776 |
0.20%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):